YMTX

Yumanity Therapeutics, Inc. [YMTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

YMTX Stock Summary

In the News

YMTX Financial details

Company Rating
-
Market Cap
15.72M
Income
-52.71M
Revenue
3.31M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-0.28
Forward P/E
-
PEG
0.03
P/S
12.98
P/B
-91.34
P/C
-
P/FCF
-0.97
Quick Ratio
0.77
Current Ratio
0.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-9.57
EPS next Y
-
EPS next Q
-
EPS this Y
-85.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
546.64%
Revenue last 5Y
-7.22%
Revenue Q/Q
-
EPS Q/Q
-1285.57%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-429%
ROE
-1267%
ROC
-55.84%
Gross Margin
100%
Oper. Margin
-5026%
Profit Margin
-4618%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.95-3.37
52W High
-
52W Low
-
RSI
-
Rel Volume
5.27
Avg Volume
132.36K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
EMBASSY.NS
MSFT
V
VOO
TL0.DE
Same Sector
RXRX
ACMSY
STAB
SRPT
LIDDS.ST
Check Those
AMK
EGORX
0I0J.L
0RUM.L
1638.HK
Similar Market Cap
IPR.LS
SUBZ
ONTX
EVLMC
IEFN

Company Profile

Healthcare Biotechnology
  • Volume Average 132.36K
  • Market Capitalization 15.72M
  • Employee 40
  • Headquarters Boston,MA,US
  • IPO Date 2016-02-11
  • Website https://www.yumanity.com

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.